Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons

Journal of Nuclear Medicine

Volumn 37, Issue 12, 1996, Pages 1923-1931

  Raffel, David M ^a   Corbett, James R ^b   Del Rosario, Renato B ^b   Gildersleeve, David L ^b   Chiao, Ping Chun ^b   Schwaiger, Markus ^b   Wieland, Donald M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

carbon 11 hydroxyephedrine; carbon 11 phenylephrine; norepinephrine transporter; PET; sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE OXIDASE (FLAVIN CONTAINING); AMIODARONE; ANTIDEPRESSANT AGENT; CARBON 11; DESIPRAMINE; NORADRENALIN; PHENYLEPHRINE;

ADRENERGIC NERVE CELL; ADULT; ARTICLE; CALCULATION; ELECTROCARDIOGRAM; FEMALE; HEART PERFUSION; HUMAN; HUMAN EXPERIMENT; ISOLATED HEART; MALE; NORADRENALIN RELEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPATHETIC TONE;

ADULT; CARBON RADIOISOTOPES; DESIPRAMINE; EPHEDRINE; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; PHENYLEPHRINE; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030469297     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Rosenspire KC, Haka MS, Van Dort ME, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-1334.
2. DeGrado T, Hutchins G, Toorongian S, Wieland D, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrme: retention mechanisms and effects of norepinephrine. J Nucl Med 1993;34:1287-1293.
3. 11C-hydroxyephedrine as marker for neuronal catecholamine retention in reperfused canine myocardium. Coronary Artery Disease 1991;2:923-929.
4. Schwaiger M, Kalff V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82:457-454.
5. Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993;22:368-375.
6. Allman K, Stevens M, Wieland D, Wolfe E, Greene D, Schwaiger M. Noninvasive assessment of cardiac diabetic neuropathy by C-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993;22:1425-1432.
7. Calkins H, Allman K, Boiling S, et al. Correlation between scintigraphic evidence of regional sympathetic neuronal dysfunction and ventricular refractoriness in the human heart. Circulation 1993;88:172-179.
8. Schwaiger M, Hutchins G, Kalff V, et al. Evidence of regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 1991;87:1681-1690.
9. Calkins H, Lehmann M, Allman K, Schwaiger M. Scintigraphic pattern of regional cardiac sympathetic innervation in patients with familial long QT syndrome using positron emission tomography. Circulation 1993;87:1616-1621.
10. DeGrado TR, Toorongian SA, Hutchins GD, Wieland DM. Characterization of C-11 m-hydroxyephedrine (HED) kinetics in isolated rat heart [Abstract]. J Nucl Med 1992;33(suppl):870-871.
11. del Rosario R, Jung Y-W, Caraher J, et al. Carbon-11 -phenylephrine. Marker for neuronal heart MAO [Abstract]. J Nucl Med 1994;35(suppl):7P.
12. del Rosario RB, Jung Y-W, Caraher J, Chakraborty PK, Sherman PS, Wieland DM. Synthesis and preliminary evaluation of [C-11] phenylephrine as a functional heart neuronal PET agent. Nucl Med Bid 1996;23:611-616.
13. Raffel DM, del Rosario RB, Tluczek L, Wieland DM. Kinetic properties of C-11 phenylephrine in isolated rat heart: effects of di-deuterium substitution, age, MAO inhibition, and reserpine [Abstract]. J Nucl Med 1995;36(suppl):90P.
14. Raffel DM, Corbett JR, Schwaiger M, Wieland DM. Mechanism-based strategies for mapping heart sympathetic nerve function. Nucl Med Biol 1995;22:1019-1026.
15. Khafagi F, Shapiro B, Fig L, Mallette S, Sisson J. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-489.
16. 11C]methyl triflale. Appl Radiat Isot 1992;43:1383-1385.
17. 11C]epinephrine for routine PET studies in humans. Nucl Med Biol 1993;20:939-944.
18. Kotzerke J, Hicks RJ, Wolfe E, et al. Three-dimensional assessment of myocardial oxidative metabolism: a new approach for regional determination of PET-derived C-11 acetate kinetics. J Nucl Med 1990;31:1876-1893.
19. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123-meta-iodobenzylguanidinc. J Nucl Med 1981;22:129-132.
20. Dae M, Herre J, O'Connell J, Botvinick E, Newman D, Munoz L. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 1991;17:1416-1423.
21. Mantysarri M, Kuikka J, Hartikainen J, et al. Myocardial sympathetic nervous dysfunction detected with I-123-M1BG is associated with low heart rate variability after myocardial infarction. J Nucl Med 1995;36:956-961.
22. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123-meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991;67:236-242.
23. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123-metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardtomyopathy. Circulation 1988;78:1192-1199.
24. Schofer J, Speilmann R, Schuchert A, Weber K, Schlüter M. Iodine-123-meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-1258.
25. Glowniak J, Turner F, Gray L, Palac R, Lagunas-Solar M, Woodward W. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989;30:1182-1191.
26. Merlet P, Valette H, Dubois-Randé J-L, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-477.
27. Rabinovitch MA, Rose CP, Schwab AJ, et al. A method of dynamic analysis of iodine-123-meta-iodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
28. Sisson J, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-1636.
29. Glowniak JV. Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. J Nucl Med 1995;36:2133-2137.
30. 18F]fluoronorepinephrine via the nucleophilic aromatic substitution reaction. J Med Chem 1991;34:767-771.
31. Eisenhofer G, Hovevey-Sion D, Kopin IJ, et al. Neuronal uptake and metabolism of 2-and 6-fluorodopamine: false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues. J Pharmacol Exper Ther 1989;248: 419-427.
32. 18F]fluorodopamine for PET studies of sympathetic nervous tissue. J Med Chem 1991;34:861-863.
33. Ding Y-S, Fowler JS, Dewey SL, et al. Comparison of high specific activity (-) and (+)-6-[F-18]fluoronorepinephrine and 6-[F-18]fluorodopamine in baboons: heart uptake, metabolism and the effect of desipramine. J Nucl Med 1993;34:619-629.
34. Schwaiger M, Wieland D, Muzik O, et al. Comparison of C-11-epinephrine and C-11 HED for evaluation of sympathetic neurons of the heart [Abstract]. J Nucl Med 1993;34(suppl):13P.
35. Pierpont G, DeMaster E, Reynolds S, Cohn J. Ventricular myocardial catecholamines in primates. J Lab Clin Med 1985;106:205-210.
36. Pierpont G, Cohn J, DeMaster E. Regional differences in adrenergic function within the left ventricle. Am J Physiol 1984;246:H824-H829.
37. Kaye MP, Tyce GM. Norepinephrine uptake as an indicator of cardiac reinnervation in dogs. Am J Physiol 1978;235:H289-H294.
38. Mathes P, Gudbjarnason S. Changes in norepinephrine stores in the canine heart following experimental myocardial infarction. Am Heart J 1971;81:211-219.
39. Angelakos ET. Regional distribution of catecholamines in the dog heart. Circ Res 1965;16:39-44.
40. 3H]-norepinephrine by the canine left ventricle. Proc Soc Exp Biol Med 1982;171:158-163.
41. 18F]nuorometaraminol. J Med Chem 1990;33:956-964.
42. Goldstein D, Brush J Jr, Eisenhofer G, Stull R, Esler M. In vivo measurement of neuronal uptake of norepinephrine in the human heart. Circulation 1988;78:41-48.
43. Esler MD, Wallin G, Dorward PK, et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol 1991;260: R817-R823.
44. Eisenhofer G, Esler MD, Meredith IT, Ferrier C, Lambert G, Jennings G. Neuronal re-uptake of noradrenaline by sympathetic nerves in humans. Clin Science 1991;80: 257-263.
45. Esler M. Clinical application of the noradrenaline spillover methodology: delineation of regional human sympathetic nervous responses. Pharmacol Toxicol 1993;73:243-253.
46. Rawlow A, Fleig H, Kurahashi K, Trendelenburg. The neuronal and extraneuronal uptake and deamination of [H-3]-(-)-phenylephrine in the perfused rat heart. Arch Pharmacol 1980;314:237-247.
47. Trendelenburg U. The extraneuronal uptake and metabolism of catecholamines. In: Weiner N, ed. Catecholamines I: handbook of experimental pharmacology, vol. 90/I. Berlin, Germany: Springer-Verlag; 1988:281-319.
48. Dae MW, De Marco T, Botvinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts - implications for clinical studies. J Nucl Med 1992;33:1444-1450.
49. Ibrahim KE, Midgley JM, Crowley JR, Williams CM. The mammalian metabolism of R-(-)-m-synephrine. J Pharm Pharmacol 1983;35:144-147.
50. Hengstmann JH, Goronzy J. Pharmacokinetics of H3-phenylephrine in man. Eur J Clin Pharmacol 1982;21:335-341.
51. Suzuki O, Matsumoto T, Oya M, Katsumata Y. Oxidation of synephrine by type A and type B monoamine oxidase. Experientia 1979;35:1283-1284.
52. Suzuki O, Hattori H. m-Octopamine as a substrate for monoamine oxidase. Life Sci 1979;25:1231-1236.
53. Suzuki O, Katsumata Y, Oya M. Oxidation of phenylethanolamine and octopamine by type A and type B monoamine oxidase: effect of substrate concentration. Biochem Pharmac 1979;28:2327-2332.
54. Suzuki O, Oya M, Katsumata Y. Oxidation of p-, m- and o-tyramine by type A and type B monoamine oxidase. Biochem Pharmacol 1979;28:2682-2684.
55. Lyles G, Holt A, Marshall C. Further studies on the metabolism of methylamine by semicarbazide-senshive amine oxidase activities in human plasma, umbilical artery and rat aorta. J Pharm Pharmacol 1990:332-338.
56. Boor PJ, Trent MB, Lyles GA, Tao M, Ansari GA, Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology 1992; 73:251-258.
57. Dar M, Bowman E. In vivo mammalian metabolism of methylamine and methylurea and their metabolic interrelationship. Drug Metab Dispos Biol Fate Chew 1985;13(6): 682-689.
58. March J. Advanced organic chemistry. 4th ed. New York. NY: John Wiley & Sons; 1992.
59. Yu PH, Bailey BA, Durden DA, Boulton AA. Stereospecific deuterium substitution at the α-carbon position of dopamine and its effects on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues. Biochem Pharmacol 1986;35: 1027-1036.
60. Tominaga T, Inoue O, Suzuki K, Yamasaki T, Hirobe M. Nitrogen-13-β-Phenethyl-amine ([N-13]PEA). A prototype tracer for measurement of MAO-B activity in heart. Biochem Pharmacol 1987;36:3671-3675.
61. 18F]fluorodopamine in living baboon heart: selective imaging and control of radiotracer metabolism using the deuterium isotope effect. J Neurochem 1995;65:682-690.
62. 11C](-)-α-α-dideutero-phenylephrine for in vivo kinetic isotope studies. J Lab Compd Radiopharm 1995;36:625-630.
63. Bajusz E, Jasmin G. Histochemical studies on the myocardium following experimental interference with coronary circulation in the rat. I. Occlusion of coronary artery. Acta Histochem 1964;18:222-237.
64. Bajusz E, Jasmin G. Observations on histochemical differential diagnosis between primary and secondary cardiomyopathies: behavior of monoamine oxidase, phosphorylase, and glycogen in heart muscle. Am Heart J 1965;69:83-92.
65. Schömig A, Kurz T, Richardt G, Schömig E. Neuronal sodium homeostasis and axoplasmic amine concentration determine calcium-independent noradrenaline release in normoxic and ischemic rat heart. Circ Res 1988;63:214-226.
66. Chidsey CA, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man. Effects of reserpinc and of congestive heart failure. N Engl J Med 1963;269:653-659.
67. Pentillä O, Kyösola K, Partanen S, Merikallio E, Siltanen P. Studies of auricular catecholamines by fluorescence histochemistry in various heart diseases of man. Virchows Arch A Pathol Pathol Anal 1977;373:279-292.
68. Borchard F, ed. The adrenergic nerves of the normal and the hypertrophied heart. In: Bargmann W, Doerr W, eds. Normal and pathological anatomy, vol. 33. Stuttgart, Germany: Georg Thieme; 1978.
69. Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am Coll Cardiol 1983;2:834-840.
70. Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest 1985;76:1740-1747.
71. Böhm M, La Roseé K, Schwinger RHG, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995;25: 146-153.
72. Sole M, Heike C, Jacobowitz D. Increased dopamine in the failing hamster heart: transvesicular transport of dopamine limits the rate of norepinephrine synthesis. Am J Cartlinl 1982;49:1682-1690.
73. Meredith I, Eisenhofer G, Lambert G, Dewar E, Jennings O, Esler M. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88: 136-145.